Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") announced today that it has entered into an ADC platform technology licensing agreement with Sidewinder Therapeutics, Inc. ("Sidewinder") of the United States. Under the licensing agreement, Escugen has granted Sidewinder a global exclusive license to use its ADC technology platform, EZWi-Fit®, for the development of ADC products targeting specific antigens.

Sidewinder will have the right to develop multiple ADC products using EZWi-Fit®, and will be responsible for the preclinical, clinical development, manufacturing, and commercial sales of these products worldwide. For each licensed product, Sidewinder will make separate payments to Escugen, including upfront payments, R&D, regulatory, and commercialization milestone payments, as well as tiered royalties on global sales after commercialization.

This collaboration marks the first direct global licensing of Escugen's next-generation ADC technology platform EZWi-Fit® to an overseas entity, signifying the high recognition of Escugen's ADC platform technology by multiple international peers.

About Escugen Biotechnology

Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on the development of innovative ADC drugs. Currently, Escugen's lead Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen's next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, anti-multiple drug resistance, and pharmacokinetic characteristics. Leveraging this platform technology, Escugen is rapidly expanding its ADC pipeline targeting new or validated targets. Escugen has also successfully licensed this platform technology to several domestic and international biotechnology companies to empower their innovative ADC projects.